Another study analyzing 2,042 endometrial cancers found HER2 amplification by next generation sequencing (NGS) in 3.8% of endometrial cancer across subtypes, including 8% of serous carcinomas, 7.1% of carcinosarcomas, 6% of clear cell carcinomas, and 0.2% of endometrioid carcinomas (Ross et al., 2022). Here, ERBB2 is linked to endometrial cancer.